Tetraphase Pharmaceuticals, Inc. announced On January 21, 2020, Steven J. Boyd and Keith Maher, M.D. were elected to the Board as Class III directors, each with a term expiring at the 2022 annual meeting of stockholders, effective upon the closing of the Private Placement. At this time, it is not contemplated that Mr. Boyd or Dr. Maher will be appointed to serve on any committees of the Board. Mr. Boyd has served since 2012 as the chief investment officer of Armistice Capital, LLC, a long-short equity hedge fund focused on the health care and consumer sectors. From 2005 to 2012, Mr. Boyd was a research analyst at Senator Investment Group, York Capital and SAB Capital Management, where he focused on health care. Dr. Maher has served as a managing director at Armistice Capital, LLC since 2019. From 2007 to 2018, Dr. Maher held senior roles at Schroder Investment Management, Omega Advisors and Gracie Capital. Dr. Maher joined Gracie from Valesco Healthcare Partners, a global healthcare fund he founded in partnership with Paramount Bio Capital. Prior to starting Valesco, Dr. Maher was a managing director at Weiss, Peck & Greer (WPG) Investments.